Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid in the treatment of COVID-19
ISRCTN12428408Phase 4Completed
- Sponsor
- Wenzhou Central Hospital
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Wenzhou Central Hospital. Primary endpoint: CT values of nasal swab SARS-CoV-2 nucleic acid tests. Started Nov 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN12428408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12428408.